Markedly decreasing azithromycin susceptibility of Neisseria gonorrhoeae, Germany, 2014 to 2021

We monitored antimicrobial susceptibility developments of Neisseria gonorrhoeae in Germany from January 2014 to May 2021. The proportion of isolates with azithromycin minimum inhibitory concentrations above the epidemiological cut-off increased substantially, from 1.3% in 2014 to 12.2% in 2020. Prel...

Descripción completa

Detalles Bibliográficos
Autores principales: Selb, Regina, Buder, Susanne, Dudareva, Sandra, Tamminga, Thalea, Bremer, Viviane, Banhart, Sebastian, Heuer, Dagmar, Jansen, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2021
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343548/
https://www.ncbi.nlm.nih.gov/pubmed/34355690
http://dx.doi.org/10.2807/1560-7917.ES.2021.26.31.2100616
_version_ 1783734310622199808
author Selb, Regina
Buder, Susanne
Dudareva, Sandra
Tamminga, Thalea
Bremer, Viviane
Banhart, Sebastian
Heuer, Dagmar
Jansen, Klaus
author_facet Selb, Regina
Buder, Susanne
Dudareva, Sandra
Tamminga, Thalea
Bremer, Viviane
Banhart, Sebastian
Heuer, Dagmar
Jansen, Klaus
author_sort Selb, Regina
collection PubMed
description We monitored antimicrobial susceptibility developments of Neisseria gonorrhoeae in Germany from January 2014 to May 2021. The proportion of isolates with azithromycin minimum inhibitory concentrations above the epidemiological cut-off increased substantially, from 1.3% in 2014 to 12.2% in 2020. Preliminary data from 2021 showed a further rise (January to May: 20.7%). Therefore, azithromycin as part of the recommended dual therapy in Germany for non-adherent patients is challenged. Antimicrobial susceptibility testing in clinical practice is crucial and continuous susceptibility surveillance indispensable.
format Online
Article
Text
id pubmed-8343548
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-83435482021-08-20 Markedly decreasing azithromycin susceptibility of Neisseria gonorrhoeae, Germany, 2014 to 2021 Selb, Regina Buder, Susanne Dudareva, Sandra Tamminga, Thalea Bremer, Viviane Banhart, Sebastian Heuer, Dagmar Jansen, Klaus Euro Surveill Rapid Communication We monitored antimicrobial susceptibility developments of Neisseria gonorrhoeae in Germany from January 2014 to May 2021. The proportion of isolates with azithromycin minimum inhibitory concentrations above the epidemiological cut-off increased substantially, from 1.3% in 2014 to 12.2% in 2020. Preliminary data from 2021 showed a further rise (January to May: 20.7%). Therefore, azithromycin as part of the recommended dual therapy in Germany for non-adherent patients is challenged. Antimicrobial susceptibility testing in clinical practice is crucial and continuous susceptibility surveillance indispensable. European Centre for Disease Prevention and Control (ECDC) 2021-08-05 /pmc/articles/PMC8343548/ /pubmed/34355690 http://dx.doi.org/10.2807/1560-7917.ES.2021.26.31.2100616 Text en This article is copyright of the authors or their affiliated institutions, 2021. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Rapid Communication
Selb, Regina
Buder, Susanne
Dudareva, Sandra
Tamminga, Thalea
Bremer, Viviane
Banhart, Sebastian
Heuer, Dagmar
Jansen, Klaus
Markedly decreasing azithromycin susceptibility of Neisseria gonorrhoeae, Germany, 2014 to 2021
title Markedly decreasing azithromycin susceptibility of Neisseria gonorrhoeae, Germany, 2014 to 2021
title_full Markedly decreasing azithromycin susceptibility of Neisseria gonorrhoeae, Germany, 2014 to 2021
title_fullStr Markedly decreasing azithromycin susceptibility of Neisseria gonorrhoeae, Germany, 2014 to 2021
title_full_unstemmed Markedly decreasing azithromycin susceptibility of Neisseria gonorrhoeae, Germany, 2014 to 2021
title_short Markedly decreasing azithromycin susceptibility of Neisseria gonorrhoeae, Germany, 2014 to 2021
title_sort markedly decreasing azithromycin susceptibility of neisseria gonorrhoeae, germany, 2014 to 2021
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343548/
https://www.ncbi.nlm.nih.gov/pubmed/34355690
http://dx.doi.org/10.2807/1560-7917.ES.2021.26.31.2100616
work_keys_str_mv AT selbregina markedlydecreasingazithromycinsusceptibilityofneisseriagonorrhoeaegermany2014to2021
AT budersusanne markedlydecreasingazithromycinsusceptibilityofneisseriagonorrhoeaegermany2014to2021
AT dudarevasandra markedlydecreasingazithromycinsusceptibilityofneisseriagonorrhoeaegermany2014to2021
AT tammingathalea markedlydecreasingazithromycinsusceptibilityofneisseriagonorrhoeaegermany2014to2021
AT bremerviviane markedlydecreasingazithromycinsusceptibilityofneisseriagonorrhoeaegermany2014to2021
AT banhartsebastian markedlydecreasingazithromycinsusceptibilityofneisseriagonorrhoeaegermany2014to2021
AT heuerdagmar markedlydecreasingazithromycinsusceptibilityofneisseriagonorrhoeaegermany2014to2021
AT jansenklaus markedlydecreasingazithromycinsusceptibilityofneisseriagonorrhoeaegermany2014to2021

Ejemplares similares